HXR9 

HXR9 is a cell-permeable peptide and a competitive antagonist of HOX/PBX interaction. HXR9 antagonizes the interaction between HOX and a second transcrip-tion factor (PBX), which binds to HOX proteins in paralogue groups1 to 8. HXR9 selectively decreases cell proliferation and promotes apoptosis in cells with a high level of expression of the HOXA/PBX3 genes, such as MLL-rearranged leukemic cells^[1][2][3].

HXR9 (60μM; 4 hours) blocks the interaction between PBX and HOX^[1].
HXR9 (60μM; 2 hours) triggers apoptosis in B16 and primary melanoma cells^[1].
HXR9 (60μM; 2 hours) causes specific transcriptional changes^[1].
HXR9 (B16 cells) shows antiproliferative activity with an IC₅₀ of 20μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

HXR9 (10 mg/kg; i.v. via the tail vein; twice weekly) blocks tumor growth^[1].
HXR9 (Initial dose of 100 mg/kg (subsequent dosing of 10 mg/kg twice weekly); Intraperitoneal; twice weekly for 18 days) blocks A549 tumour growth in vivo^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2718.21

C₁₁₉H₁₉₃N₅₃O₂₀S

917953-08-3

Trp-Tyr-Pro-Trp-Met-Lys-Lys-His-His-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg

WYPWMKKHHRRRRRRRRR

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Morgan R, et al. Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. Cancer Res. 2007;67(12):5806-5813.  [Content Brief]

  [2]. Li Z, et al. PBX3 is an important cofactor of HOXA9 in leukemogenesis. Blood. 2013;121(8):1422-1431.  [Content Brief]

  [3]. Plowright L, et al. HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer). Br J Cancer. 2009;100(3):470-475.  [Content Brief]